[Direct positive inotropic cardiac effect of aldactone (spironolactone, canrenoate-K)].
D000284:Administration, Oral; D001835:Body Weight; D002245:Carbon Dioxide / Q000097:blood; D002986:Clinical Trials as Topic; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004338:Drug Combinations; D004357:Drug Synergism; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006914:Hydroxysteroids / Q000627:therapeutic use; D007664:Ketosteroids / Q000627:therapeutic use; D008297:Male; D010100:Oxygen / Q000097:blood; D011278:Pregnanes / Q000627:therapeutic use*; D011422:Propionates / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use*
D004071:Digitalis Glycosides; D004338:Drug Combinations; D006914:Hydroxysteroids; D007664:Ketosteroids; D011278:Pregnanes; D011422:Propionates; D002245:Carbon Dioxide; D013148:Spironolactone; D010100:Oxygen
Direkte positiv-inotrope Herzwirkung von Aldactone (Spironolacton, Canrenoat-Kalium.